Michele Malagola
A5030528628- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Lymphoma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Histone Deacetylase Inhibitors Research
- Cytomegalovirus and herpesvirus research
- Retinoids in leukemia and cellular processes
- Protein Degradation and Inhibitors
- Mesenchymal stem cell research
- Hemoglobinopathies and Related Disorders
- Antifungal resistance and susceptibility
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- Mycobacterium research and diagnosis
- Frailty in Older Adults
- Hematological disorders and diagnostics
- Fungal Infections and Studies
- Cancer Genomics and Diagnostics
University of Brescia
2016-2025
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2016-2025
Gruppo Italiano per il Trapianto di Midollo Osseo
2023
Brescia University
2005-2019
National Marrow Donor Program
2019
University Medical Center Groningen
2019
University Cancer Center Hamburg
2019
University Medical Center Hamburg-Eppendorf
2019
Universität Hamburg
2019
Istituto di Ematologia di Bologna
2017
Abstract Several papers authored by international experts have proposed recommendations on the management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these recommendations, survival CML patients has become very close to normal. The next, ambitious, step is bring as many possible into a condition treatment-free remission (TFR). Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA; Italian Group for Hematologic Diseases Adult) Working Party (WP) developed project aimed at...
A Deep Molecular Response (DMR), defined as a BCR::ABL1 transcript at levels ≤ 0.01% by RT-qPCR, is the prerequisite for successful interruption of treatment among patients with Chronic Myeloid Leukemia (CML). However, approximately 50% in Treatment-Free Remission (TFR) studies had to resume therapy after their rose above 0.1% threshold. To improve detection sensitivity and accuracy, can be analyzed using digital PCR (dPCR). dPCR increases 10–100 fold; however, its ability better select TFR...
ABSTRACT Chronic Myeloid Leukemia (CML) is characterized by the BCR::ABL1 fusion gene, driving uncontrolled myeloid cell proliferation. Furthermore, metabolic dysregulation contributes to disease progression. Despite efficacy of tyrosine kinase inhibitors (TKIs), unresolved clinical needs persist, necessitating refined preclinical models. This study compared responses three commonly used CML lines (K562, LAMA84, KCL22) five TKIs (imatinib, nilotinib, dasatinib, bosutinib, ponatinib) and a...
Abstract Treatment‐free remission (TFR) by tyrosine kinase inhibitors (TKI) discontinuation in patients with deep molecular response (DMR) is a paramount goal the current chronic myeloid leukemia (CML) therapeutic strategy. The best DMR level real‐time quantitative PCR (RT‐qPCR) for TKI still matter of debate. To compare accuracy digital (dPCR) and RT‐qPCR BCR‐ABL1 transcript levels detection, 142 CML were monitored median time 24 months. Digital detected transcripts undetectable cases. dPCR...
Letermovir (LMV) inhibits HCMV replication by binding to components of the HCMV-terminase complex showing a potential role in prevention HCMV-related complications allogenic hematopoietic stem cell transplant recipients (allo-HSCTRs). However, little is known about breakthrough infection and relevance DNAemia during prophylaxis. We reported results multicenter prospective study involving five Italian centers management 75 adult HCMV-seropositive allo-HSCTRs undergoing LMV The aim present was...
Abstract Purpose: This phase II prospective study aimed to evaluate the efficacy and safety of 5-days azacytidine (5d-AZA) in patients with low-risk myelodysplastic syndromes (MDS). Second, single-nucleotide polymorphism (SNP) genetic profile phosphoinositide-phospholipase C (PI-PLC) β1 levels were studied possible biologic markers able predict hematologic response. Experimental Design: The tested a lower intensity schedule azacytidine. treatment plan consisted 75 mg/sqm/d subcutaneous...
We performed a nationwide registry-based analysis to describe the clinical outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who underwent an allogeneic hematopoietic stem cell transplantation (HSCT) after tyrosine kinase inhibitor (TKI)-based treatment A total 441 were included in study. The median age at HSCT was 44 years (range, 18 70 years). All (100%) received TKI before (performed between 2005 and 2016). Of these patients, 404 (92%)...
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL studyThe anti-CD38 antibody daratumumab, currently approved for the treatment of patients multiple myeloma, is also being explored leukemia (ALL), whose blasts commonly express high levels CD38. 1 Patients (R/R) disease, as well those positive measurable residual disease (MRD) have consistently shown unfavorable outcomes and, especially T-lineage ALL,...
Extracorporeal photopheresis (ECP) is considered a valid second-line treatment for acute and chronic graft versus host disease (GVHD).Ninety-four patients with GVHD (aGVHD) (n = 45) (cGVHD) 49), retrospectively recruited in 6 Italian centers, were submitted to ECP treatment. At the time of ECP, 22 (49%) 23 (51%) 45 aGHVD nonresponsive partial remission (PR) after steroids, respectively, all 49 cGVHD steroid refractory.Forty-one (91%) aGVHD achieved complete (CR) ECP. Fifteen (33%) developed...
A human bone marrow-derived mesenchymal stromal cell (MSCs) and cord blood-derived CD34+ stem co-culture system was set up in order to evaluate the proliferative differentiative effects induced by MSCs on cells, reciprocal influences gene expression profiles. After 10 days of co-culture, non-adherent (SN-fraction) adherent (AD-fraction) cells were collected analysed separately. In presence MSCs, a significant increase number observed (fold = 14.68), mostly SN-fraction 13.20). This combined...
Due to the discovery of their role in intra‑cellular communications, exosomes, which carry information specific cell origin, have garnered considerable attention cancer research. Moreover, there is evidence suggest possibility isolating different exosome sub‑populations based on target antigens at surface. Philadelphia chromosome‑positive (Ph+) chronic myeloid leukemia (CML) a clonal myeloproliferative neoplasia characterized by breakpoint cluster region‑proto‑oncogene 1 tyrosine‑protein...
Sinusoidal obstruction syndrome (SOS), also known as veno-occlusive disease (VOD), is a rare but potentially fatal complication following allogenic hematopoietic cell transplantation (allo-HCT). Timely identification of SOS/VOD to allow for prompt treatment critical, identifying VOD-predictive biomarker remains challenging. Given the pivotal role endothelial dysfunction in pathophysiology, CECinVOD study prospectively evaluated levels circulating cells (CECs) patients undergoing allo-HCT...
Chronic Myeloid Leukemia (CML) is marked by the BCR::ABL1 fusion gene. Monitoring tyrosine kinase inhibitor (TKI) therapy response crucial for treatment management, thus, limitations in Reverse Transcription quantitative PCR's (RT-qPCR) accuracy and sensitivity led to exploration of alternative methods like digital PCR (dPCR). This study evaluated dPCR efficacy detecting Minimal Residual Disease (MRD) CML patients undergoing TKI therapy. 79 were enrolled (NP 3809 clinical trial), with...
Antibody-targeted chemotherapy is a promising approach in patients with hematological malignancies. In particular, gemtuzumab ozogamicin (GO, formerly CMA-676), an anti-CD33 antibody linked to calicheamicin, has been approved for the treatment of elderly acute myeloid leukemia (AML) relapse. Nevertheless, no data are until now available concerning possible efficacy GO sarcomas (MS). We treated 24 AML patients, 5 cases presenting skin or bones. The overall complete response rate was 21%....